(MedPage Today) — Less than a year after approval, Pfizer said it plans to discontinue its hemophilia B gene therapy fidanacogene elaparvovec (Beqvez) across all global markets, citing weak demand.
“Pfizer has made the decision to cease further…
Source link : https://www.medpagetoday.com/hematologyoncology/hemophilia/114319
Author :
Publish date : 2025-02-21 16:27:24
Copyright for syndicated content belongs to the linked Source.
